A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis

Clinical Therapeutics

Volumn 24, Issue 12, 2002, Pages 1998-2021

  Zhang, Jingwu ^a   Hutton, George ^a   Zang, Ying ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Glatiramer acetate; Interferon beta; Multiple sclerosis

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; BETA1 INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; AUTOIMMUNITY; CLINICAL MEDICINE; HUMAN; IMMUNE SYSTEM; MEDLINE; MULTIPLE SCLEROSIS; PHENOTYPE; PROTEIN EXPRESSION; PUBLISHING; REGULATORY MECHANISM; REVIEW; SCISEARCH; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; UNITED STATES;

EID: 0036931817     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80094-7     Document Type: Review

References (138)

1. Comi G, Filippi M, Wolinsky JS, for the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49:290-297.
2. Comi G, Filippi M, Wolinsky J, for the European/Canadian Glatiramer Acetate Study Group. The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in patients with relapsing-remitting multiple sclerosis. Neurology. 2001;56(Suppl 3):A255. Abstract.
3. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
4. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
5. Jacobs LD, Cookfair DL, Rudick RA, et al, for the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
6. Johnson KP, Brooks BR, Cohen JA, et al, for the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a Phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45:1268-1276.
7. Paty DW, Li DK, for the UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
8. Rudick RA, Fisher E, Lee JC, et al, for the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53:1698-1704.
9. Simon JH, Jacobs LD, Campion M, et al, for the Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol. 1998;43:79-87.
10. Arnason BG, Dayal A, Qu ZX, et al. Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin Immunopathol. 1996;18:125-148.
11. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995;37:7-15.
12. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343:37-49.
13. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000;343:108-117.
14. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
15. Becher B, Blain M, Giacomini PS, Antel JP. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J Immunol. 1999;162:684-688.
16. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol. 2000;12:114-121.
17. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-264.
18. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell. 1995;80:707-718.
19. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995;182:1985-1996.
20. Teleshova N, Bao W, Kivisakk P, et al. Elevated CD40 ligand expressing blood T-cells in multiple sclerosis are reversed by interferon-β treatment. Scand J Immunol. 2000;51:312-320.
21. Kozovska ME, Hong J, Zang YC, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999;53:1692-1697.
22. Rep MH, Hintzen RQ, Polman CH, van Lier RA. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996;67:111-118.
23. Huang YM, Kouwenhoven M, Jin YP, et al. Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. Mult Scler. 2001;7:95-99.
24. Huang YM, Stoyanova N, Jin YP, et al. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10. Clin Exp Immunol. 2001;124:306-314.
25. Huang YM, Hussien Y, Yarilin D, et al. Interferon-beta induces the development of type 2 dendritic cells. Cytokine. 2001;13:264-271.
26. Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. 2001;112:153-162.
27. Karp CL, Biron CA, Irani DN. Interferon β in multiple sclerosis: Is IL-12 suppression the key? Immunol Today. 2000;21:24-28.
28. McRae BL, Semnani RT, Hayes MP, van Seventer GA. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol. 1998;160:4298-4304.
29. McRae BL, Beilfuss BA, van Seventer GA. IFN-β differentially regulates CD40-induced cytokine secretion by human dendritic cells. J Immunol. 2000;164:23-28.
30. Munschauer FE, Hartrich LA, Stewart CC, Jacobs L. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol. 1995;62:177-181.
31. Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189-220.
32. Rice GP, Casali P, Merigan TC, Oldstone MB. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Ann Neurol. 1983;14:333-338.
33. Kastrukoff LF, Morgan NG, Zecchini D, et al. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol. 1998;86:123-133.
34. Kastrukoff LF, Morgan NG, Zecchini D, et al. Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon β-1B. Neurology. 1999;52:351-359.
35. Perini P, Wadhwa M, Buttarello M, et al. Effect of IFNβ and anti-IFNβ antibodies on NK cells in multiple sclerosis. J Neuroimmunol. 2000;105:91-95.
36. Wen L, Barber DF, Pao W, et al. Primary γδ cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation. J Immunol. 1998;160:1965-1974.
37. Wucherpfennig KW, Newcombe J, Li H, et al. γδ T-cell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci U S A. 1992;89:4588-4592.
38. Stinissen P, Vandevyver C, Medaer R, et al. Increased frequency of gamma delta T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity and T cell receptor V gene rearrangements. J Immunol. 1995;154:4883-4894.
39. Elliott CL, El-Touny SY, Filipi ML, et al. Interferon β1a treatment modulates TH1 expression in γδ+ T cells from relapsing-remitting multiple sclerosis patients. J Clin Immunol. 2001;21:200-209.
40. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin-10 levels in multiple sclerosis: Further evidence for decreased systemic immunosuppression? J Neurol. 1996;243:13-17.
41. Waubant E, Gee L, Bacchetti P, et al. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol. 2001;112:139-145.
42. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995;37:82-88.
43. Musette P, Benveniste O, Lim A, et al. The pattern of production of cytokine mRNA is markedly altered at the onset of multiple sclerosis. Res Immunol. 1996;147:435-441.
44. Balashov KE, Comabella M, Ohashi T, et al. Defective regulation of IFNγ and IL-12 by endogenous IL-10 in progressive MS. Neurology. 2000;55:192-198.
45. Killestein J, Den Drijver BF, Van der Graaf WL, et al. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: Different features in primary progressive disease. Mult Scler. 2001;7:145-150.
46. Brod SA, Nelson LD, Khan M, Wolinsky JS. Increased in vitro induced CD4+ and CD8+ T cell IFN-γ and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis. Int J Neurosci. 1997;90:187-202.
47. Durán I, Martínez-Cáceres EM, Brieva L, et al. Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis. Mult Scler. 2001;7:151-156.
48. Neuhaus O, Hartung HP. In search of a disease marker: The cytokine profile of primary progressive multiple sclerosis. Mult Scler. 2001;7:143-144.
49. Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol. 1995;154:2959-2968.
50. Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med. 1998;187:537-546.
51. de Goer de Herve MG, Delfraissy JF, Taoufik Y. Following direct CD40 activation, human primary microglial cells produce IL-12 p40 but not bioactive IL-12 p70. Cytokine. 2001;14:88-96.
52. Fassbender K, Ragoschke A, Rossol S, et al. Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation. Neurology. 1998;51:753-758.
53. Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol. 1996;70:87-90.
54. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol. 1999;45:695-703.
55. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 1998;102:671-678.
56. Özenci V, Pashenkov M, Kouwenhoven M, et al. IL-12/IL-12R system in multiple sclerosis. J Neuroimmunol. 2001;114:242-252.
57. Hussien Y, Sanna A, Söderström M, et al. Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosis. J Neuroimmunol. 2001;121:102-110.
58. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-β in multiple sclerosis: Altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol. 2001;14:361-368.
59. Tuohy VK, Yu M, Yin L, et al. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J Neuroimmunol. 2000;111:55-63.
60. Özenci V, Kouwenhoven M, Huang YM, et al. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-β-1b treatment. Scand J Immunol. 1999;49:554-561.
61. Rep MH, Schrijver HM, van Lopik T, et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmmunol. 1999;96:92-100.
62. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology: 1998;50:1294-1300.
63. Wang A, Chen M, Wandinger KP, et al. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-β-1b therapeutic effects in multiple sclerosis. J Immunol. 2000; 165:548-557.
64. Zang YC, Yang D, Hong J, et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000;55:397-404.
65. Becher B, Giacomini PS, Pelletier D, et al. Interferon-γ secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-β therapy. Ann Neurol. 1999;45: 247-250.
66. Furlan R, Bergami A, Lang R, et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4. J Neuroimmunol. 2000; 111:86-92.
67. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology. 1987;37:1097-1102.
68. Skurkovich S, Boiko A, Beliaeva I, et al. Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis. Mult Scler. 2001;7:277-284.
69. Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001;50:349-357.
70. Rogge L, D'Ambrosio D, Biffi M, et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol. 1998;161:6567-6574.
71. Dayal AS, Jensen MA, Lledo A, Arnason BG. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995;45: 2173-2177.
72. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996;47:1531-1534.
73. Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53:457-465.
74. Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998;4:78-83.
75. Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156:5-7.
76. Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157: 3223-3227.
77. Lafaille JJ, Keere FV, Hsu AL, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from disease. J Exp Med. 1997;186:307-312.
78. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 1996; 274:2054-2057.
79. + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999;96:6873-6878.
80. Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807-815.
81. Van Der Voorn P, Tekstra J, Beelen RH, et al. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol. 1999;154:45-51.
82. Zang YC, Samanta AK, Halder JB, et al. Aberrant T cell migration toward RANTES and MIP-1α in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain. 2000; 123:1874-1882.
83. Zhang GX, Baker CM, Kolson DL, Rostami AM. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler. 2000;6:3-13.
84. Zang YC, Halder JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β. J Neuroimmunol. 2001; 112:174-180.
85. Dubois B, Opdenakker G, Carton H. Gelatinase B in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neurol Belg. 1999;99:53-56.
86. Lee MA, Palace J, Stabler G, et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 1999;122: 191-197.
87. Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol. 2000;107: 140-147.
88. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40:846-852.
89. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview. J Neuroimmunol. 1997;72:155-161.
90. Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol. 1998;44:35-46.
91. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol. 1996;55:300-309.
92. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999;53:1397-1401.
93. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 1998;121:2327-2334.
94. Özenci V, Rinaldi L, Teleshova N, et al. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun. 1999;12:297-303.
95. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neurol. 1996;40:853-863.
96. Lou J, Gasche Y, Zheng L, et al. Interferon-β inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest. 1999;79:1015-1025.
97. Trojano M, Avolio C, Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology. 1999; 53:1402-1408.
98. Özenci V, Kouwenhoven M, Teleshova N, et al. Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β. J Neuroimmunol. 2000;108:236-243.
99. Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest. 1999;104:527-529.
100. Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000;55:178-184.
101. Hong J, Tejada-Simon MV, Rivera VM, et al. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002;8:237-242.
102. Teitelbaum D, Aharoni R, Arnon R, Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci U S A. 1988;85:9724-9728.
103. Racke MK, Martin R, McFarland H, Fritz RB. Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation. J Neuroimmunol. 1992;37:75-84.
104. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A. 1992; 89:137-141.
105. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity. Proc Natl Acad Sci U S A. 1994;91: 4872-4876.
106. Fridkis-Hareli M, Strominger JL. Promiscuous binding of synthetic copolymer I to purified HLA-DR molecules. J Immunol. 1998;160:4386-4397.
107. Ben-Nun A, Mendel I, Bakimer R, et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease. J Neurol. 1996;243(Suppl 1):S14-S22.
108. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol. 1996;64:209-217.
109. Fridkis-Hareli M, Neveu JM, Robinson RA, et al. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol. 1999;162:4697-4704.
110. Fridkis-Hareli M, Stern JN, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses. Hum Immunol. 2001;62:753-763.
111. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A. 1999;96:634-639.
112. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56:702-708.
113. Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology. 2000;55: 1704-1714.
114. Ragheb S, Abramczyk S, Lisak D, Lisak R. Long-term therapy with glatiramer acetate in multiple sclerosis: Effect on T-cells. Mult Scler. 2001;7:43-47.
115. Wiesemann E, Klatt J, Sönmez D, et al. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J Neuro-immunol. 2001;119:137-144.
116. Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105:967-976.
117. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997;94:10821-10826.
118. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998;91:135-146.
119. Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A. 2000;97:11472-11477.
120. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler. 2001;7:209-219.
121. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109:641-649.
122. Farina C, Then Bergh F, Albrecht H, et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells. Brain. 2001;124:705-719.
123. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-α) does not improve experimental autoimmune encephalomyelitis. Ann Neurol. 2000;47:127-131.
124. Pilaro AM, Sayers TJ, McCormick KL, et al. An improved in vitro assay to quantitate chemotaxis of rat peripheral blood large granular lymphocytes (LGL). J Immunol Methods. 1990;135:213-223.
125. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol. 1986;119:558-573.
126. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59:1496-1506.
127. Herndon RM Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care [serial online]. 1999; 2:1-6. Available at: http://mscare.com. Accessed August 10, 2002.
128. Rudick RA, Simonian NA, Alam JA, et al, for the Multiple Sclerosis Collaborative Research Group (MSCRG). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 1998;50:1266-1272.
129. European Study Group on Interferonβ-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferonβ-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497.
130. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology. 1996;47:889-894.
131. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res. 1998;18:345-350.
132. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
133. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56:1628-1636.
134. Huang YM, Hussien Y, Jin YP, et al. Multiple sclerosis: Deficient in vitro responses of blood mononuclear cells to IFN-beta. Acta Neurol Scand. 2001;104: 249-256.
135. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann Neurol. 1996;40:618-627.
136. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993;34:661-669.
137. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 1997;49:862-869.
138. Prat A, Al-Asmi A, Duquette P, Antel JP. Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy. Ann Neurol. 1999;46:253-256.